|
Cenix BioScience Expands Usage of Definiens Technology
in High-Content Screening
By deploying Definiens’ image analysis platform, Cenix
BioScience achieves higher hit rates, improved accuracy and greater reliability
in its advanced RNA interference research services.
Munich, 12. February, 2008
- Definiens, the number one Enterprise Image Intelligence™ Company and
Cenix BioScience GmbH, the leading specialist in advanced high throughput (HT)
RNA interference (RNAi)-based research services, announced today that they have
expanded their mutual licensing agreement. This strategic decision confirms the
heightened commitment of Cenix to the use of the Definiens technology within its
organization. Resulting from the findings of an internal review Definiens
Cellenger® was reselected as the best available application to support Cenix in
the development and implementation of high content (HC) microscopy assays for
HT-RNAi studies in cultured human and rodent cells.
Definiens Cellenger is Definiens advanced application for high content analysis
that enables the reliable and fully automated extraction of data from images
used in cell-based assays. It allows Cenix to analyze structures of interest
even in complex images with high accuracy. The flexible and platform-independent
application automates and standardizes the company’s image analysis processes -
of particular use with multi-parametric cell-based assays. For this innovative
technology, Definiens gained the 2007 Frost & Sullivan Technology Leadership
Award in the US high-content screening market, which is based on a detailed
analysis of the high content screening market executed by Frost & Sullivan.
With Definiens Cellenger Cenix is able to handle the most challenging demands of
image analysis tasks, covering every assay development need. The application
will be integrated into the existing HT/HC-RNAi-based research infrastructure at
Cenix, enabling the widest possible range of advanced microscopy-based assays in
its research service offerings.
Dr. Michael Hannus, Group Leader, Cell-based Discovery & Validation at Cenix
BioScience, said “After we tested and reviewed the available high content
screening software, it became obvious that there is no other solution out there
that can support us in the extremely challenging image analysis tasks we perform
for our customers.”
Cenix BioScience provides research services to the life science industry and the
academic community, focusing on the combination of HT-RNAi with HC assays in
human and rodent cells. In its efforts to further strengthen its capabilities in
microscopy-based screening and automated image analysis, Cenix BioScience
reviewed a wide range of image analysis solutions offered by academia and
industry.
“We are pleased with Cenix‘s decision to intensify the use of our product in its
laboratories,” stated Rene Hermes, Vice President Marketing, Definiens. “Its
decision is recognition of the unmatched possibilities that our technology
offers to customers for developing automated image analysis applications.”
About Cenix BioScience GmbH
Cenix BioScience GmbH is a pioneer and global leader in the convergence of high
throughput (HT), genomics-driven applications of RNA interference (RNAi) with
high content, multi-parametric cell-based assays. Founded in 1999 as the first
biotechnology company specializing in HT-RNAi, Cenix has accumulated
unparalleled depth and breadth of experience in this field, using human and
rodent cell models in a wide range of disease indications, including oncology,
atherosclerosis, diabetes, obesity, neurodegenerative disorders and infectious
diseases such as malaria. Cenix offers its unique expertise to industry and
academic researchers through fully customizable research services, focusing on
the discovery and validation of novel therapeutic drug targets and the analysis
of drug mechanisms of action. Please contact Cenix or visit the company’s web
site www.cenix-bioscience.com for
more information.
Definiens in Life Sciences
By automating image analysis
on an enterprise level, Definiens supports Life Science organizations to analyze
and interpret vast numbers of images accurately and consistently. Definiens
improves the measurement of cell assays, the examination of tissue samples and
the interpretation of non-invasive imaging, enabling high-content screening,
digital pathology and translational medicine.
About Definiens
Definiens is the number one Enterprise Image Intelligence company for analyzing
and interpreting images on every scale, from microscopic cell structures to
satellite images. The Definiens Cognition Network Technology®, developed by
Nobel laureate Prof. Gerd Binnig and his team, is an advanced and robust
context-based technology designed to fulfill the
image analysis
requirements of the Life and Earth sciences markets. The technology is modeled
on the powerful human cognitive perception processes to extract intelligence
from images. Definiens provides organizations with faster image analysis results,
allowing deeper insights enabling better business decisions. The company is
headquartered in Munich, Germany and has offices throughout the United States.
Further information is available at
www.definiens.com.
Definiens, Definiens Cellenger, Definiens Cognition Network Technology,
Definiens eCognition, Enterprise Image Intelligence and Understanding Images are
trademarks or registered trademarks of Definiens.
Press contact:
|
